STOCK TITAN

Fortress Biotech Inc - FBIO STOCK NEWS

Welcome to our dedicated news page for Fortress Biotech (Ticker: FBIO), a resource for investors and traders seeking the latest updates and insights on Fortress Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Fortress Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Fortress Biotech's position in the market.

Rhea-AI Summary
Fortress Biotech, Inc. reported a record consolidated net revenue of $84.5 million for the full-year 2023. The company may receive up to four regulatory decisions on NDAs and BLAs in the next 18 months. The FDA accepted the New Drug Application filing for DFD-29 to treat inflammatory lesions and erythema of rosacea in adults, with a PDUFA goal date of November 4, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Summary
Checkpoint Therapeutics, Inc. announces financial results for full-year 2023 and corporate updates. The company plans to resubmit a Biologics License Application for cosibelimab by mid-year for potential approval before 2024 end. Checkpoint remains confident in the clinical data and safety package.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.11%
Tags
earnings
-
Rhea-AI Summary
Checkpoint Therapeutics, Inc. announces financial results for full-year 2023 and corporate updates. The company plans to resubmit a Biologics License Application for cosibelimab by mid-year for potential approval before 2024 end. Checkpoint remains confident in the clinical data and safety package.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
earnings
Rhea-AI Summary
Journey Medical (DERM) reports total revenues of $79.2 million for 2023, a 7% increase from 2022. Operating cost savings of $15.6 million exceeded guidance. New Drug Application for rosacea treatment candidate DFD-29 accepted by FDA with a PDUFA goal date of November 4, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.61%
Tags
earnings
-
Rhea-AI Summary
Journey Medical (DERM) reports total revenues of $79.2 million for 2023, a 7% increase from 2022. Operating cost savings of $15.6 million exceeded guidance. New Drug Application for rosacea treatment candidate DFD-29 accepted by FDA with a PDUFA goal date of November 4, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
earnings
-
Rhea-AI Summary
Journey Medical (DERM) announces FDA acceptance of NDA for DFD-29 for rosacea treatment with a PDUFA goal date of November 4, 2024. Positive Phase 3 trial data supports the efficacy and safety of DFD-29.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
clinical trial
Rhea-AI Summary
Journey Medical (DERM) announces FDA acceptance of NDA for DFD-29 for rosacea treatment with a PDUFA goal date of November 4, 2024. Positive Phase 3 trial data supports the efficacy and safety of DFD-29.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
clinical trial
-
Rhea-AI Summary
Journey Medical (DERM) to host conference call to discuss financial results and provide corporate update on March 21, 2024. The company focuses on selling FDA-approved prescription pharmaceutical products for dermatological conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
earnings
-
Rhea-AI Summary
Journey Medical (DERM) to host conference call to discuss financial results and provide corporate update on March 21, 2024. The company focuses on selling FDA-approved prescription pharmaceutical products for dermatological conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.18%
Tags
earnings
Rhea-AI Summary
Journey Medical Corporation (DERM) will participate in the 36th Annual ROTH Conference, with the President and CEO engaging in a fireside chat and one-on-one meetings. A webcast of the chat will be accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
conferences
Fortress Biotech Inc

Nasdaq:FBIO

FBIO Rankings

FBIO Stock Data

39.88M
6.58M
28.08%
25.68%
8.38%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About FBIO

fortress biotech, inc. is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. fortress plans to develop and commercialize products that it acquires both directly as well as indirectly by establishing subsidiary companies, also known as fortress companies. the company will leverage its biopharmaceutical business expertise and drug development capabilities to help the fortress companies achieve their goals. additionally, the company will provide funding and management services to each of the fortress companies and from time to time the company and the fortress companies will seek licensing, partnerships, joint ventures, and/or public and private financings to accelerate and provide additional funding to support their research and development programs.